Thrombosis
News
Factor can prevent bleeding in hemophilia A
Researchers found that prophylaxis with rFVIIIFc resulted in low annualized bleeding rates, and patients did not develop neutralizing antibodies...
News
New drug stacks up well against warfarin
AMSTERDAM—The oral anticoagulant edoxaban compares favorably with warfarin as treatment for recurrent venous thromboembolism (VTE), according to...
News
AMPLIFY: Apixaban beat warfarin on safety in acute VTE
Major finding: Major bleeds occurred in 0.6% of patients on apixaban and 1.8% of patients on warfarin, with similar efficacy. Data source: The...
News
Fraud, errors were behind delay of apixaban approval, report shows
Medication mistakes, reporting errors, and record changes are what led the US Food and Drug Administration (FDA) to delay approval of the...
News
Fusion protein controls surgery-related bleeding in hemophilia B
AMSTERDAM—A recombinant factor IX Fc fusion protein (rFIXFc) can control bleeding among hemophilia B patients undergoing major surgery, according...
News
New antiplatelet drug seems more effective than standard
SAN FRANCISCO—The novel antiplatelet agent cangrelor is more effective than clopidogrel as thromboprophylaxis for patients undergoing coronary...
News
FDA again rejects rivaroxaban for ACS
For a second time, the FDA has decided against approving rivaroxaban (Xarelto) to reduce the risk of cardiovascular events in patients with acute...
News
Dabigatran noninferior to warfarin for preventing recurrent VTE
New research suggests dabigatran is noninferior to warfarin as extended prophylaxis for recurrent venous thromboembolism (VTE), and warfarin...
News
New antihemophilic factors last longer than standard treatments
Data from the phase 3 A-LONG study indicated that patients with hemophilia A could maintain low bleeding rates with once- to twice-weekly...
News
FDA approves plasma product
The FDA has approved a pooled plasma blood product (Octaplas) that can be used to replace coagulation factors in patients with certain medical...
News
FDA approves apixaban for patients with NVAF
The agency’s decision is based on results of the ARISTOTLE trial, in which NVAF patients taking apixaban experienced fewer strokes than those on...